Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Mol Carcinog. 2016 Sep 22;56(3):1182–1188. doi: 10.1002/mc.22550

Figure 4:

Figure 4:

Calu-6 and HOP-62 (xenografts were injected intratumorally daily either with 200 μM CMK or with vehicle alone. Tumors were measured every two or three days. Volume changes of both types of xenografts showed a reduction of volume after CMK treatment (A &B) (P=0.04 and 0.06). Solid line (control), dotted line (CMK treatment). Better levels of significance (P=0.001 and 0.01 for Calu-6 and HOP-62 respectively) were seen when the mitotic index (evaluated as labeling index of p-Histone 3) in paraffin sections at the last time point of treatment (control versus CMK treated tumors) were compared. Values are expressed in the y axis as mean number of positively stained nuclei/microscopic field ± SEM (C). Panels D to E show the immunohistochemical detection of p-Histone 3 in Calu- 6 control xenografts (D), Calu-6 xenografts treated with CMK (E), HOP-62 xenografts control (F) and HOP-62 xenograft treated with CMK (G). The latter four panels were stained with p-Histone 3 IHC, counterstained with hematoxylin and digitally photographed at X200.